Segall Bryant & Hamill LLC Makes New Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Segall Bryant & Hamill LLC purchased a new stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 45,100 shares of the company’s stock, valued at approximately $712,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Prudential Financial Inc. lifted its stake in Dr. Reddy’s Laboratories by 250.8% in the 4th quarter. Prudential Financial Inc. now owns 135,400 shares of the company’s stock valued at $2,138,000 after acquiring an additional 96,800 shares in the last quarter. Angeles Investment Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 341.1% in the fourth quarter. Angeles Investment Advisors LLC now owns 18,597 shares of the company’s stock worth $294,000 after purchasing an additional 14,381 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Dr. Reddy’s Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after purchasing an additional 3,911,404 shares during the last quarter. LPL Financial LLC grew its position in Dr. Reddy’s Laboratories by 418.7% in the fourth quarter. LPL Financial LLC now owns 128,126 shares of the company’s stock valued at $2,023,000 after purchasing an additional 103,424 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Dr. Reddy’s Laboratories in the fourth quarter valued at $95,000. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $13.20 on Friday. The stock has a market capitalization of $11.01 billion, a PE ratio of 21.01 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.50 and a 1-year high of $16.89. The firm has a fifty day simple moving average of $13.48 and a 200 day simple moving average of $14.61. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.